Genscript Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Genscript Biotech CEO'su Weihui Shao, Jul2021 tarihinde atandı, in görev süresi 3.33 yıldır. in toplam yıllık tazminatı $ 2.48M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.3% maaş ve 85.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.034% ine doğrudan sahiptir ve bu hisseler € 927.93K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 1.7 yıldır.

Anahtar bilgiler

Weihui Shao

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi	14.3%
CEO görev süresi	3.3yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	1.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Weihui Shao'un ücretlendirmesi Genscript Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

Tazminat ve Piyasa: Weihui 'ın toplam tazminatı ($USD 2.48M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.97M ).

Tazminat ve Kazançlar: Weihui şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Weihui Shao (44 yo)

3.3yrs

Görev süresi

US$2,477,000

Tazminat

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Weihui Shao	CEO & COO	3.3yrs	US$2.48m	0.034% € 927.9k
Ye Wang	Co-Founder	22.8yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	no data	Veri yok	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	1.9yrs	US$531.00k	Veri yok
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Shiniu Wei	Chief Financial Officer	3.9yrs	Veri yok	Veri yok
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	no data	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: G51 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Ye Wang	Co-Founder	9.5yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	9.5yrs	Veri yok	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	2.5yrs	US$531.00k	Veri yok
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Carl June	Member of Advisory Board	less than a year	Veri yok	Veri yok
George Church	Member of Advisory Board	5.2yrs	Veri yok	Veri yok
Alphonse Galdes	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
David Liu	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Chenyang Shi	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Ethan Pan	Independent Non-Executive Director	less than a year	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: G51 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Genscript Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

New major risk - Share price stability

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Now 22% undervalued after recent price drop

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 22% undervalued after recent price drop

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

New major risk - Share price stability

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

New minor risk - Share price stability

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold €159k worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Now 20% undervalued

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold €246k worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold €988k worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: €1.40

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: €1.06

New 90-day low: €1.08

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: €1.25

Co-Founder recently bought €410k worth of stock

First half earnings released

New 90-day low: €1.28

First half earnings released

New 90-day low - €1.60

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

New 90-day low - €1.66

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi